Skip to main content
Majority of new cancer drugs don't extend, improve life, study finds

For a large percentage of new and costly cancer drugs, often approved for use in Europe based on surrogate endpoints, data in the years after approval failed to show extended overall survival or improved quality of life, according to a study in the British Medical Journal. The FDA is also increasingly relying on endpoints other than overall survival and quality of life changes, Dr. Vinay Prasad wrote in an accompanying editorial.

Full Story: